Ulcerative colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatment

Authors
Category Primary study
JournalGastroenterology
Year 2017
This article has no abstract
Epistemonikos ID: 006a82dc6f3d485a076ad8cea41a27efb06e5103
First added on: Feb 08, 2025